Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.65 |
| ▸ | CA1 | P00915 | 3/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | CA5A | P35218 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teclothiazide SCHEMBL7621916 | 0.91 | LMNA (0.83) | LMNACA1CA2CA7HTT | |
| SCHEMBL11929107 | 0.84 | TDP1 (0.48) | LMNACA1CA2CA7HTT | |
| SCHEMBL29132609 | 0.81 | TDP1 (0.70) | LMNACA1CA2CA7HTT | |
| SCHEMBL29376961 | 0.81 | TDP1 (0.70) | LMNACA1CA2CA7HTT | |
| SCHEMBL20369162 | 0.81 | LMNA (0.46) | LMNACA1CA2CA7HTT | |
| SCHEMBL11837435 | 0.81 | TDP1 (0.51) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL29356280 | 0.79 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL25493 | 0.79 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| SCHEMBL13685945 | 0.79 | TDP1 (0.79) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL25492 | 0.79 | LMNA (1.00) | LMNACA1CA2CA7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | ABBVIE DEUTSCHLAND (DE) | 2017-03-23 | — | — | US | claimed |
| US-8865650-B2 | Therapy for complications of diabetes | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-21 | — | — | US | claimed |
| US-20140073574-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-13 | — | — | US | claimed |
| US-8623819-B2 | Therapy for complications of diabetes | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-07 | — | — | US | claimed |
| US-20130178424-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-12-23 | — | — | US | claimed |
| US-20100152217-A1 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION | GILEAD SCIENCES, INC. | 2010-06-17 | — | — | US | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030060489-A1 | Novel method of treatment | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-27 | — | — | US | claimed |
| EP-1261373-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SmithKline Beecham plc (GB) | 2002-12-04 | — | — | EP | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| WO-2001047509-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073574-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | LMNA 2176/4885CA1 4839/4885CA2 3858/4885 |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | LMNA 1336/4885CA1 1067/4885CA2 217/4885 |
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | LMNA 2132/4885CA1 4841/4885CA2 3868/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | LMNA 3648/4885CA1 610/4885CA2 585/4885 |
| US-20100323012-A1 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics | ECE1, EDNRA, MME | LMNA 410/4885CA1 2697/4885CA2 555/4885 |
| US-20130178424-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | LMNA 2176/4885CA1 4839/4885CA2 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.